Response to Comments: MolDX: Breast Cancer Assay: Prosigna

MolDx received no comments on the draft MolDX: Breast Cancer Assay: Prosigna policy during the formal comment period. As a result, no new coverage indications, limitations, documentation requirements, or frequency limits were identified or changed. No further action or updates to coverage criteria are reported in this document.